A Randomized, Open, Single-dose, 3 Period Partial Replicated Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of CKD-333 or Co-administration of CKD-330 and D085 in Healthy Volunteers Under Fasting Conditions
Latest Information Update: 07 Nov 2022
At a glance
- Drugs Amlodipine/candesartan-cilexetil (Primary) ; CKD-333 (Primary) ; D 086 (Primary)
- Indications Cardiovascular disorders
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 19 Nov 2020 New trial record